SRC and cancer: Indeed, SRC pathway activation has been positively correlated with sensitivity to treatment with dasatinib and saracatinib in different cancer types [44,45,46], suggesting that SRC activation could potentially serve as a biomarker to guide SRC targeting and clinical efficacy.